Market open
Emergent BioSolutions/$EBS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Ticker
$EBS
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
900
Website
EBS Metrics
BasicAdvanced
$334M
-
-$3.60
1.80
-
Price and volume
Market cap
$334M
Beta
1.8
52-week high
$15.10
52-week low
$1.82
Average daily volume
1.3M
Financial strength
Current ratio
3.687
Quick ratio
1.564
Long term debt to equity
137.469
Total debt to equity
137.469
Interest coverage (TTM)
0.60%
Management effectiveness
Return on assets (TTM)
-2.03%
Return on equity (TTM)
-33.67%
Valuation
Price to revenue (TTM)
0.312
Price to book
0.69
Price to tangible book (TTM)
-17.86
Price to free cash flow (TTM)
4.954
Growth
Revenue change (TTM)
-0.54%
Earnings per share change (TTM)
-75.76%
3-year revenue growth (CAGR)
-16.20%
3-year earnings per share growth (CAGR)
-3.93%
What the Analysts think about EBS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
EBS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
EBS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
EBS News
AllArticlesVideos
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
GlobeNewsWire·4 hours ago
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
GlobeNewsWire·1 day ago
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Emergent BioSolutions stock?
Emergent BioSolutions (EBS) has a market cap of $334M as of March 13, 2025.
What is the P/E ratio for Emergent BioSolutions stock?
The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 0 as of March 13, 2025.
Does Emergent BioSolutions stock pay dividends?
No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next Emergent BioSolutions dividend payment date?
Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.
What is the beta indicator for Emergent BioSolutions?
Emergent BioSolutions (EBS) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.